Erythropoietin-derived peptide aimed at neuropathy and inflammation without raising RBC.
Typical dose range: 1–4 mg
Frequency: Daily
Route: Subcutaneous
Half-life: Minutes
Evidence level: Phase 2
Designed to deliver EPO's tissue-protective effects without the haematocrit spike. Of interest to diabetics with neuropathy.